Are GLP-1s Bad for Your Kidneys?

The research points the other way. In the large kidney trials, GLP-1 medications slowed the progression of kidney disease, and semaglutide now carries an FDA-approved indication for doing exactly that in adults with type 2 diabetes and chronic kidney disease.

The worry people arrive with isn't unfounded, though. There's a real way these medications can strain your kidneys. It shows up in the prescribing information, and it works through dehydration rather than the drug acting on kidney tissue.

Where the Worry Comes From

Ask around and you'll hear some version of "these drugs are hard on your kidneys," usually with no source attached. It has roots in a few real things. Kidneys filter what's in your blood, so anything you take weekly for a year invites the question. Early postmarketing reports of acute kidney injury in GLP-1 users made the news. And people on these medications do sometimes get sick enough to end up in an emergency department with a creatinine that's climbed.

The direction of the evidence runs the other way. Nephrology has spent the last two years studying these medications in kidney trials, and the results were strong enough that the FDA expanded a label on the strength of them.

What the Kidney Trials Found

FLOW was built to answer this. Researchers randomized 3,533 adults with type 2 diabetes and chronic kidney disease to weekly semaglutide 1.0 mg or placebo on top of standard care, including ACE inhibitors or ARBs. Baseline kidney function was already impaired, with a mean eGFR of 47. The trial was stopped early for efficacy. Major kidney events, a composite of kidney failure, a sustained 50% drop in eGFR, or death from kidney or cardiovascular causes, occurred in 18.7% of the semaglutide group and 23.2% of the placebo group, a 24% relative reduction over a median 3.4 years.¹ All-cause death was lower too, 12.8% versus 15.8%.¹

Those results are why the FDA added an indication in January 2025 for semaglutide at diabetes doses "to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease."³

The Badve meta-analysis pulled together 11 randomized trials and 85,373 participants. In the type 2 diabetes population, GLP-1s reduced the composite kidney outcome by 18% and kidney failure by 16% against placebo.² The authors also folded in SELECT, which enrolled people with a BMI of 27 or higher and cardiovascular disease but no diabetes, and the effect held at 19% with no meaningful heterogeneity between that trial and the diabetes trials.² That's the closest thing we have to evidence in a non-diabetic population, though SELECT participants all had established cardiovascular disease, so they're still not the average weight-loss patient.

SURPASS-CVOT compared tirzepatide with dulaglutide, another GLP-1, in 13,165 adults with type 2 diabetes and cardiovascular disease. Over a median four years, the composite kidney outcome hit 6.0% on tirzepatide versus 7.6% on dulaglutide, a 23% reduction, with tirzepatide also slowing the annual decline in eGFR.⁶

Three different designs and populations pointed the same way. None of them studied people with healthy kidneys taking a weight-management dose, which is the honest limit on all of it.

How a GLP-1 Actually Strains Your Kidneys

The mechanism is mundane. The most common side effects of these medications are nausea, vomiting, and diarrhea. Lose enough fluid through any of those and your blood volume drops, which means less blood reaching your kidneys, which is how acute kidney injury happens in a person whose kidneys were fine the week before.

The semaglutide label puts it plainly under a heading called Acute Kidney Injury Due to Volume Depletion: there have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, and "the majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea."⁴ The tirzepatide label carries the same warning in nearly identical language.⁵

The rates in controlled trials are low. Acute kidney injury showed up in 7 patients on semaglutide 2.4 mg, 0.4 cases per 100 patient-years, against 4 patients on placebo at 0.2 per 100 patient-years.⁴ For tirzepatide, 0.5% versus 0.2% on placebo.⁵ Risk was higher in people who already had impaired kidney function, and events happened more often during dose escalation.⁴

That second point is the argument for titrating slowly and staying in contact with someone while you do it. A week of vomiting you power through alone is the scenario that lands people in trouble, and it's the one a check-in catches. We go through the practical side of managing nausea in our guide to managing GLP-1 side effects.

Why Your eGFR Might Look Different After Weight Loss

Some people finish six months of a GLP-1 program, run labs, and see their eGFR has shifted. The number can move for reasons that have nothing to do with the kidney.

Standard eGFR is calculated from serum creatinine, and creatinine is a breakdown product of muscle. Lose meaningful muscle mass and your creatinine falls, which nudges your estimated kidney function up even if nothing changed inside the kidney. Lose weight without protecting muscle and the number flatters you. This is part of why KDIGO's 2024 guideline recommends estimating GFR from creatinine and cystatin C together when cystatin C is available, since cystatin C doesn't track muscle mass the same way.⁷

Timing matters too. FLOW measured its eGFR effect as a slope across years rather than a single before-and-after comparison, and the benefit there showed up as a slower annual decline in kidney function.¹ One lab drawn a few weeks into a program isn't a trend, whichever direction it moves.

In practice that means a baseline draw before you start, then comparing later labs against it with muscle mass protected in between. Protein intake and resistance training are what keep the muscle side honest, and we get into the measurement piece in tracking body composition on a GLP-1.

Who Needs to Be More Careful

Existing kidney disease is the clearest flag. The trial evidence says these medications may support kidney function in that group, and the same labels say renal adverse reactions were more frequent in people with a history of renal impairment.⁴ Both are true, and the resolution is a provider who knows your eGFR before you start rather than after.

A few other situations raise the stakes on a bad GI week:

• Taking a diuretic, an ACE inhibitor, or an ARB, which affect how your kidneys handle a drop in blood volume
• Regular NSAID use, meaning ibuprofen and naproxen
• A history of kidney stones or a single functioning kidney
• Heavy training in heat, where you're already running a fluid deficit
• Age over 65, where fluid loss is tolerated less well

Kidney impairment doesn't meaningfully change how semaglutide is processed, so drug accumulation isn't the concern here.³ What matters is your fluid status when you get sick.

What to Watch For at Home

Call your provider if you've had more than about 24 hours of vomiting or diarrhea you can't get ahead of, or if you notice urinating much less than usual, dark or tea-colored urine, swelling in your ankles or face, or unusual confusion or lightheadedness when you stand.

Most of the time the fix is simple and early. Fluids, electrolytes, pausing NSAIDs, and a conversation about your dose. The cases that turn serious are usually the ones where someone waited a week because they assumed feeling awful was part of the deal.

How We Monitor It at Defiant

Every weight loss protocol here starts with labs, and kidney function is on the panel. We write the order and you get drawn at your primary care office or through Rythm Health, since we don't draw blood in-clinic. Details on what else we look at are in our walkthrough of what happens at a first medical weight loss consultation.

After that, the Custom GLP-1 Protocol runs bi-weekly titration check-ins rather than monthly, which is mostly about catching side effects while they're still small. Nausea that's making you skip fluids is something we'd rather hear about in week three than at a 90-day follow-up. Monthly Styku 3D body scans track whether you're holding muscle, which matters for how your labs read as well as for how you feel.

Program pricing starts at $295 a month and includes the medication, provider oversight, bi-weekly check-ins, monthly body composition scans, and nurse access between visits. We're at 5100 Lincoln Ave in Lisle, IL, seeing patients from Naperville, Downers Grove, Wheaton, Bolingbrook, Lombard, and across Chicago's western suburbs.

Frequently Asked Questions

Last updated September 22, 2026.